CERC is very proud to announce the launch of a new app designed to help identify High Bleeding Risk patients : ARC HBR As a member of the Academic Research Consortium, CERC developed a specific mobile application to identify High Bleeding Risk patients : The ARC-HBR evaluator is modelled on a consensus definition of High Bleeding Risk (HBR) for patients who are candidates for treatment with a coronary stent. Very easy to use, the evaluator helps physicians at the bedside to quickly identify HBR patients. Click on the picture below to discover this highly valued new tool. The full text of the ARC-HBR definition has been published in the European Heart Journal and Circulation. To learn more, watch the video below about « High-bleeding risk patients: Guidelines and recommendations from the ARC HBR...
A very interesting article published in JACC Cardiovascular Intervention about our VIVA trial: > Read the very positive editorial from Danny Dvir and Vinnie Bapat > Read the hole paper & get more information about...
CERC was founded in 2008 by a group of interventional cardiologists who firmly believed in the need for establishing a new CRO dedicated to Cardiology to enhance the quality and increase the numbers of clinical studies initiated in Europe. Our self-assigned mission, supported by our industrial and pharmaceutical partners, was to design groundbreaking clinical studies with the purpose of redefining medical practice in order to improve our patients’ outcomes. The international, multicultural team that we have been gradually building at CERC is composed of high level scientists from various backgrounds (15 languages are currently spoken at CERC) who have enabled us to become a highly reputable clinical research organization. We are very proud to have achieved our initial objective of successfully carrying out clinical trials with the invaluable involvement of physicians and medical device companies. We have been instrumental in helping many centers to undertake clinical research studies for the first time and we have guided them throughout their journey to becoming very efficient investigating centers. Other renowned cardiologists have joined CERC’s founding group and their experience and expertise have enriched CERC’s strategies. CERC has already conducted numerous major studies and is currently coordinating many more. We are extremely grateful to all our sponsors for the trust they have placed in us, to the physicians who have contacted us with innovative ideas for original studies, to the investigators and study coordinators who have been tirelessly enrolling patients, to our teams in CERC, CERC Asia and CERC Deutschland who strive daily to bring these studies to fruition, to the CEC and DSMB members who have offered their knowledge and their...
« I am most excited to partner CERC Asia to get the Biofreedom STEMI registry. STEMI FREE would provide a great opportunity to investigate the STEMI population in Asia in a scientifically robust manner. The use of Biofreedom stent in Primary Angioplasty should be the logical next step to explore the unique Biolimus property in ACS patients and how the polymer free stent perform in “unknown bleeding risk” ACS subjects.« Paul Ong, Principal investigator of the BiofFreedom Stemi Free Registry I am looking forward to working closely with like minded investigators across Asia to run the study. The chance to make new friends and explore budding trial sites will be equally rewarding. I am very grateful for placing the trust in me. I am confident that with the expertise and support from CERC Asia we can deliver a well conducted study with robust clinical data. This is the beginning of a beautiful partnership in...
CERC was proud to organize the first ARC HBR meeting in Washington’s American College of Cardiology last Friday 13th of April...
